Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Cancers|August 26, 2022
Recent Advances and Challenges in Cancer ImmunotherapyChelsea Peterson, Nathan Denlinger, Yiping Yang
Current Problems in Cancer|January 11, 2022
CAR T-cell therapy for B-cell lymphomaNathan Denlinger, David Bond, Samantha Jaglowski
Frontiers in Immunology|August 30, 2024
Stem-like CD8<sup>+</sup> T cells in cancerChelsea Steiner, Nathan Denlinger, Xiaopei Huang, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 20, 2024
SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell ProgramTimothy J Voorhees, Evandro Bezerra, Nathan Denlinger, et al.
Transplantation and Cellular Therapy|October 1, 2020
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter AnalysisAdam S Kittai, Ying Huang, Max Gordon, et al.
Endocrinology|November 26, 2014
Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD miceKelly D McCall, Jean R Thuma, Maria C Courreges, et al.
Transplantation and Cellular Therapy|March 6, 2022
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell LymphomaAudrey M Sigmund, Nathan Denlinger, Ying Huang, et al.
Transplantation and Cellular Therapy|June 24, 2026
Outcomes of Tocilizumab for Cytokine Release Syndrome After Post-Transplant CyclophosphamideTuan L Phan, Roberta Azbell, Hannah Choe, et al.
Blood Advances|October 22, 2024
Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysisAmneet Bajwa, Qiuhong Zhao, Marcus Geer, et al.
Experimental Hematology & Oncology|September 22, 2023
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma modelsWing Keung Chan, Jessica Williams, Kinnari Sorathia, et al.
Pageof 3